Plasma cell depletion as an approach to reset autoimmunity in rheumatoid arthritis

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511536-27-00

Acronym

CURACTA

Enrollment

Registered

2024-03-13

Start date

2025-03-11

Completion date

Unknown

Last updated

2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Brief summary

Incidence and grading of severity of Injection Related Reactions (IRR) and toxicity after administration of daratumumab until week 12, AE and SAE due to IMP (both, daratumumab and abatacept) throughout the whole study, Percentage of subjects with ACPA seroconversion (below the laboratory reference level for positivity)

Interventions

DRUGDARZALEX 1800 mg solution for injection

DRUGORENCIA 125 mg solution for injection in pre-filled syringe

DRUGORENCIA 125 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and grading of severity of Injection Related Reactions (IRR) and toxicity after administration of daratumumab until week 12, AE and SAE due to IMP (both, daratumumab and abatacept) throughout the whole study, Percentage of subjects with ACPA seroconversion (below the laboratory reference level for positivity)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026